// App-Quantinova.ai

24 : A Randomized, Double-Blind, Placebo-Controlled, Phase-2B Study to Evaluate the Safety and Efficacy of Recombinant Human Soluble Thrombomodulin, ART-123, in Patients with Sepsis and Suspected Disseminated Intravascular Coagulation

Researchers

Presenter

  • Kazuhisa Tsuruta

Principal Investigators

  • Kenneth Gorelick

  • Yutaka Osawa

  • Debra Hoppensteadt

  • Jawed Fareed

  • Jean-Louis Vincent

Medical Centers

  • N/A

Locations

  • N/A

Companies

  • Asahi Kasei Medical

Study Components

Therapeutic Area

  • Infectious Diseases (ID)

Disease

  • Disseminated intravascular coagulation

  • Sepsis

  • Venous thrombosis

Biomarkers

  • Collagen type IV alpha 2 chain

  • D-dimer

  • Folate Hydrolase 1

Drug/Treatment

  • Thrombomodulin alfa

  • Protein C

  • Evithrom

  • Heparin

Outcome

  • N/A

Study Design

  • randomized

  • double blind/blinded

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved